GRAFTON, Ohio, March 20, 2019 (GLOBE NEWSWIRE) -- Item 9 Labs Corp. (OTC: INLB) (Item 9 Labs or the Company), a leading developer and manufacturer of innovative cannabis products and proprietary delivery platforms, today announced CEO Sara Gullickson and African-American Advisory Board Members Donald Burton and Larry K. Lemons were awarded a processor provisional license for Strive Wellness of Ohio, LLC. The entity qualified as a disadvantaged group due to its minority-led ownership team.
Item 9 Labs is in the process of negotiating a partnership agreement with Strive Wellness of Ohio to fund the management of the operation and introduce the Company’s diverse product suites. Item 9 Labs was ranked one of the fastest growing concentrate brands in Arizona and will enter the Nevada market later this year.
Strive Wellness of Ohio was acknowledged as one of the top scoring applicants in the highly competitive licensing process. The Medical Marijuana Control Program at the Ohio Department of Commerce received 104 processor applications for 40 licenses.
The provisional license authorizes Strive Wellness of Ohio to begin construction and to secure applicable local permits in order to pursue its Certificate of Operation. The proposed facility will be located in Grafton City, Lorain County, covering 7,000 square-feet on a property parcel compliant with zoning requirements.
“The real estate we secured allows for additional expansion so we can meet patient demands as the Ohio program grows,” stated Sara Gullickson. “We look forward to bringing trusted and innovative cannabis health solutions to the Ohio Market.”
Ohio dispensaries took in more than $300,000 in their first month of sales, outpacing other medical markets including Massachusetts and Hawaii.
Item 9 Labs will be operating as licensed dispensaries, cultivation, and manufacturing facilities in a projected ten U.S. markets by the end of 2019.
For information visit Item9labscorp.com.
About Item 9 Labs Corp.:
Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, one of the largest properties in the U.S. zoned to grow and cultivate the medical marijuana flower. Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of today's modern cannabis consumer. For more information, visit us online at www.Item9labscorp.com and www.Item9labs.com.
Forward-Looking Statement:
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Media Contact:
Neko Catanzaro
Proven Media
Neko@provenmediaservices.com
(401)-484-4980
Investor Contact:
Jeffrey Rassas
Item 9 Labs Corp.
Jeffrey@item9labs.com
(602)463-4246